JCO precision oncology (Journal)

Activity: Publication peer-review and editorial workPublication peer-review


Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib
in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type
Melanoma (TraMel-WT)
Gil Awada, MD, PhD1 ; Iris Dirven, MD1 ; Julia Katharina Schwarze, MD, MSc1; Jens Tijtgat, MD1; Giuseppe Fasolino, MD2;
Mark Kockx, MD, PhD3; and Bart Neyns, MD, PhD1
DOI https://doi.org/10.1200/PO.23.00493
Period14 Feb 2024
Type of journalJournal